The first successful case of ABO-incompatible living-donor lobar lung transplantation following desensitization therapy

Am J Transplant. 2023 Sep;23(9):1451-1454. doi: 10.1016/j.ajt.2023.04.031. Epub 2023 May 4.

Abstract

ABO-incompatible (ABO-I) living-donor lobar lung transplantation (LDLLT) was successfully performed in a 14-year-old girl who suffered from bronchiolitis obliterans due to graft-versus-host disease following hematopoietic stem cell transplantation. In the ABO-I LDLLT procedure, the blood type O patient received a right lower lobe donated from her blood type B father and a left lower lobe donated from her blood type O mother. Desensitization therapy, using rituximab, immunosuppressants, and plasmapheresis, was implemented for 3 weeks prior to transplantation to reduce the production of anti-B antibodies in the recipient and prevent acute antibody-mediated rejection after ABO-I LDLLT.

Keywords: ABO-incompatible; desensitization; living donor; lung transplantation; plasmapheresis; rituximab.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Female
  • Humans
  • Immunosuppressive Agents
  • Living Donors*
  • Lung Transplantation* / adverse effects
  • Rituximab
  • Treatment Outcome

Substances

  • Rituximab
  • Immunosuppressive Agents